Estimating treatment effects for individual patients based on the results of randomised clinical trials. - Wikidata - wikimedia - TriplyDB

Estimating treatment effects for individual patients based on the results of randomised clinical trials.

Estimating treatment effects for individual patients based on the results of randomised clinical trials.

http://www.wikidata.org/entity/Q35252544

about

Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study Cognitive-Behavioural Analysis System of Psychotherapy (CBASP), a drug, or their combination: differential therapeutics for persistent depressive disorder: a study protocol of an individual participant data network meta-analysis A generalised model for individualising a treatment recommendation based on group-level evidence from randomised clinical trials Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia.Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH).Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines.Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement.Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. The TRIPOD Group.Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program.Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research.IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women Machine Learning for Treatment Assignment: Improving Individualized Risk Attribution.LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder.Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.Development and validation of clinical prediction models for mortality, functional outcome and cognitive impairment after stroke: a study protocol.New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality: A Validation and Clinical Decision-making Study.Tailoring treatments using treatment effect modification.Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction.Projecting diabetes prevalence among Mexicans aged 50 years and older: the Future Elderly Model-Mexico (FEM-Mexico).Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement.Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement.Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.The path to personalized vascular therapy - We are closer than we think.Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicentre pragmatic trial.Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatments.Development and evaluating multimarker models for guiding treatment decisions.

P2860

Q28484624-319276DA-59D6-40EB-96A9-7AEF3F67EF7B Q28603042-899D6897-37F3-4548-B644-8C561C4A153E Q30543580-3358EC1D-9FEB-49A9-86E4-14EBAD6FA8B5 Q31112168-DA27127A-76E6-4796-B5E4-F1D1B3ECBE64 Q31143342-67B50234-76A2-4673-83ED-77D8FEDA0888 Q33764787-346F9974-822F-4E76-A290-F4A2C3B2F482 Q34506218-4C9A300F-CA7C-40FC-93FE-2B0F65D38FC6 Q34538048-B123D855-67BE-457D-A423-C4EADE4E83FD Q34542774-862E4CDF-6040-4DB4-832D-4D2F0BCCF840 Q34837497-74714487-B65F-4959-9BC2-0F3CDC9AE2AD Q34978306-895EC960-97F8-4524-95EF-D4C48FBE8D7D Q35158163-13157934-7001-4DFF-83CD-A302485431B1 Q35583564-AB593E2F-137E-45C9-83F2-F0BB668BADC9 Q35669168-A86F0D2C-D78B-4394-95D6-1D83B69DFF39 Q35691372-4C520164-45D1-4092-B622-D971F288B8E4 Q35953560-7B01D796-1363-4E28-9252-885E4018385C Q36613424-587623D9-B37A-4A16-A2D7-4A3D18E2B213 Q36965468-1C04C2A3-9D09-446D-B628-314B92C938EF Q37446677-D70A8FFC-5BF5-4287-A96F-AC8FAE95CCA4 Q37580870-BDFB44D2-F5F2-4E78-83D1-8FC1BAE1B197 Q37642390-BF209CC8-EF67-446D-9B9A-839F06297B1E Q38380588-D2B232BA-64E0-4B0E-A9D7-12BB2F4A1631 Q38618088-F273B6DE-A515-4E9B-8F91-ED867BDD53E4 Q38725994-BD28B972-D5D5-452A-B743-0B080F8C51E5 Q38733650-4BA34231-9211-4EE4-B947-92F0DF2D0015 Q42656681-A931B846-825F-4F8C-A00C-093217638131 Q42687747-6CD43C08-A5D2-4385-85A7-1FE078CFFF3A Q42699413-0C3B500D-857E-40C8-9305-2FD6B7C619BC Q51150112-17DF4AA9-8E96-409B-BDD2-12BE2F77FEE8 Q51150478-536C3656-30F5-4476-994E-64430B9A572F Q51152907-2FB61F44-183E-47B6-AB56-EF3C2167DF2B Q51157282-C26E8835-DE8E-428C-BF31-B348E4EAA00F Q51561810-0827A862-5B0C-48FC-8A7B-DBFBA7E89405 Q53756303-4BCAC988-D442-4551-BD02-4F5BD3C24C54 Q53830840-2C71C784-BA08-4932-B4F1-EC96D451DA28 Q55000441-494AE064-A8FB-42D5-A803-CA9EAF4C5AAC Q55489099-E9859269-973D-4EF8-A877-47C53ED5BC0C

P2860

Estimating treatment effects for individual patients based on the results of randomised clinical trials.

http://www.wikidata.org/entity/Q35252544

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Estimating treatment effects f ...... of randomised clinical trials.

@ast

Estimating treatment effects f ...... of randomised clinical trials.

@en

type

label

Estimating treatment effects f ...... of randomised clinical trials.

@ast

Estimating treatment effects f ...... of randomised clinical trials.

@en

prefLabel

Estimating treatment effects f ...... of randomised clinical trials.

@ast

Estimating treatment effects f ...... of randomised clinical trials.

@en

P1433

Q35252544-7F12F3D1-0D06-4FDD-82BD-D83D0B9EAC0D

P1476

Q35252544-F129CC9A-4FDF-4939-9EB8-2EF5CFF4301F

P2093

Q35252544-33A1126F-06FB-4D06-8A43-1FA796846E70

Q35252544-35C63AF8-EFFE-4CEE-858D-8AC2AF766619

Q35252544-548A9056-5986-4958-A48E-43E500E1688D

Q35252544-586E4592-412F-4165-A8E1-ADBA2EE0530C

Q35252544-CE2383A2-D8E2-40AF-87B8-297AC40BFECD

Q35252544-F6DD72A6-E805-4089-ABDE-D0E2012493F9

Q35252544-F83AA34F-C441-47E6-8833-0D8BCEF8F999

P2860

Q35252544-17EA340A-0EF7-4479-9C4B-8474CD960143

Q35252544-31A79D51-9916-43CE-8C2C-6FAAA3961C82

Q35252544-31D85AE7-91B4-4668-8D0B-2DF65C9B58E9

Q35252544-56A520D0-72AB-4253-8153-800086D9EA8C

Q35252544-5CA13A5B-958A-40A2-99A6-C7CCAA6CEB9F

Q35252544-5D725454-5CCA-4F75-8CE1-7B0D2449670D

Q35252544-6B73DA0C-1020-42AE-85A1-4C086DE1E6E0

Q35252544-7273232B-8C3C-4CEF-8E9C-A60BE0509AF9

Q35252544-806845A7-E5E0-4513-86BB-68AC6AA38EBA

Q35252544-82C52385-1149-4D11-8002-D26B447AED28

P304

Q35252544-83204F87-3436-402D-B14F-64A126256CB0

P31

Q35252544-79F73E09-6FAB-4CC5-9A6B-451E27BD2CE3

P356

Q35252544-1BEECFFA-4804-48C0-B636-3A8DB129883D

P407

Q35252544-AA69A53B-D8D3-41E2-B8AA-7A58F8E0BC50

P433

Q35252544-3220DB47-84AA-4174-9D63-65522C559ADA

P478

Q35252544-E38ED126-F489-48DC-99B8-CC9E2698A8DD

P50

Q35252544-87D02738-CB81-4279-A6FE-80579A885B9E

P577

Q35252544-273F62C4-5E00-4E73-9E22-0AE061398CB5

P5875

Q35252544-699FEAB4-1A93-456F-B1AD-0125E7373767

P698

Q35252544-D3746D3F-7C1B-4910-A5DA-68C5F3A6B1B7

P932

Q35252544-74B09481-6ECA-4807-9AB7-CFB298D16ECF

P356

P1433

P1476

Estimating treatment effects f ...... of randomised clinical trials.

@en

P2093

Annemarie M J Wassink

http://www.w3.org/2001/XMLSchema#string

Frank L J Visseren

http://www.w3.org/2001/XMLSchema#string

Johannes A N Dorresteijn

http://www.w3.org/2001/XMLSchema#string

Nancy R Cook

http://www.w3.org/2001/XMLSchema#string

Nina P Paynter

http://www.w3.org/2001/XMLSchema#string

Paul M Ridker

http://www.w3.org/2001/XMLSchema#string

Yolanda van der Graaf

http://www.w3.org/2001/XMLSchema#string

P2860

Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Method for evaluating prediction models that apply the results of randomized trials to individual patients

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Decision curve analysis: a novel method for evaluating prediction models

Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

P304

d5888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.D5888

http://www.w3.org/2001/XMLSchema#string

P407

P433

oct03 1

http://www.w3.org/2001/XMLSchema#string

P478

343

http://www.w3.org/2001/XMLSchema#string

P50

Ewout W. Steyerberg

P577

2011-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51689842

http://www.w3.org/2001/XMLSchema#string

P698

21968126

http://www.w3.org/2001/XMLSchema#string

P932

3184644

http://www.w3.org/2001/XMLSchema#string